Recognition and management of excessive sleepiness in the primary care setting

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 11, Issue 5, 2009, Pages 197-204

  Schwartz, Jonathan R L ^a   Roth, Thomas ^b   Hirshkowitz, Max ^c   Wright, Kenneth P ^d  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b Henry Ford Sleep Disorder Center   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78349267554     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.07r00545     Document Type: Review

References (81)

1. Pigeon WR, Sateia MJ, Ferguson RJ. Distinguishing between excessive daytime sleepiness and fatigue: toward improved detection and treatment. J Psychosom Res. 2003;54(1):61-69.
2. Zepf B. Problem sleepiness: an often unrecognized condition. Am Fam Physician. 1999;59(4):762, 770, 773.
3. National Sleep Foundation. 2002 Adult Sleep Habits. 2002 "Sleep in America Poll." http://www.sleepfoundation.org/article/sleep-america-polls/2002-adult-sleep-habits.
4. Committee on Sleep Medicine and Research. Board on Health Sciences Policy. Institute of Medicine of the National Academies. Colten HR, Altevogt BM, eds. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington, DC: The National Academies Press; 2006
5. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalo-graphic slow waves, and sleep spindle activity in humans. J Neurosci. 1995;15:3526-3538.
6. Borbely AA, Achermann P. Sleep homeostasis and models of sleep regulation. J Biol Rhythms. 1999;14(6):557-568.
7. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 2nd edition: Diagnostic and Coding Manual. Westchester, IL: American Academy of Sleep Medicine; 2005.
8. Shen J, Barbara J, Shairo CM. Distinguishing sleepiness and fatigue: focus on definition and measurement. Sleep Med Rev. 2006;10(1):63-76.
9. Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest. 2000;118(2):372-379.
10. Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. J Clin Psychiatry. 2004;65(suppl 16):12-16.
11. D'Alessandro R, Rinaldi R, Cristina E, et al. Prevalence of excessive daytime sleepiness: an open epidemiological problem. Sleep. 1995; 18(5):389-391.
12. Kushida CA, Nichols DA, Simon RD, et al. Symptom-based prevalence of sleep disorders in an adult primary care population. Sleep Breath. 2000;4(1):9-14.
13. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl). 2004;176(1):1-29.
14. Wehr TA, Moul DE, Barbato G, et al. Conservation of photoperiod-responsive mechanisms in humans. Am J Physiol. 1993;265:R846-R857.
15. Roehrs T, Timms V, Zwyghuizen-Doorenbos A, et al. Sleep extension in sleepy and alert normals. Sleep. 1989;12(5):449-457.
16. Carskadon MA, Dement WC. Cumulative effects of sleep restriction on daytime sleepiness. Psychophysiology. 1981;18(2):107-113.
17. Dinges DF, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor performance decrements during a week of sleep restricted to 4-5 hours per night. Sleep. 1997;20(4):267-277.
18. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328(17): 1230-1235.
19. Young T, Evans L, Finn L, et al. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997;20(9):705-770.
20. Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinol Metab Clin North Am. 2003;32(4):869-894.
21. Tauman R, Gozal D. Obesity and obstructive sleep apnea in children. Paediatr Respir Rev. 2006;7(4):247-259.
22. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469-474.
23. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 2000.
24. Drake CL, Roehrs T, Richardson G, et al. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep. 2004;27(8):1453-1462.
25. Reimer MA, Flemons WW. Quality of life in sleep disorders. Sleep Med Rev. 2003;7(4):335-349.
26. Thorpy MJ. Which clinical conditions are responsible for impaired alertness? Sleep Med. 2005;6(suppl 1):S13-S20.
27. Baldwin CM, Griffith KA, Nieto FJ, et al. The association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health Study. Sleep. 2001;24(1):96-105.
28. Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. Semin Neurol. 2005;25(1):117-129.
29. Lockley SW, Cronin JW, Evans EE, et al. Effect of reducing interns' weekly work hours on sleep and attentional failures. N Engl J Med. 2004;351(18):1829-1837.
30. Landrigan C P, Rothschild JM, Cronin JW, et al. Effect of reducing interns' work hours on serious medical errors in intensive care units. N Engl J Med. 2004;351(18):1838-1848.
31. Dinges DF. An overview of sleepiness and accidents. J Sleep Res. 1995; 4(S2):4-14.
32. Stutts JC, Wilkins JW, Scott-Osberg J, et al. Driver risk factors for sleep-related crashes. Accid Anal Prev. 2003;35(3):321-331.
33. Barger LK, Cade BE, Ayas NT, et al. Extended work shifts and the risk of motor vehicle crashes among interns. N Engl J Med. 2005;352(2): 125-134.
34. Lyznicki JM, Doege TC, Davis RM, et al, for the Council on Scientific Affairs. Sleepiness, driving, and motor vehicle accidents. JAMA. 1998; 279(23):1908-1913.
35. National Commission on Sleep Disorders Research. Report of the National Commission on Sleep Disorders Research. Washington, DC: Government Printing Office; 1992.
36. Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep. 1994;17(1):84-93.
37. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540-545.
38. Hoddes E, Dement W, Zarcone V. The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiology. 1972;9:150.
39. Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990;52(1-2):29-37.
40. Krupp LB, LaRocca NG, Muir-Nash J, et al. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythe-matosus. Arch Neurol. 1989;46(10):1121-1123.
41. Chalder T, Berelowitz G, Hirsch S, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147-153.
42. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the Fatigue Impact Scale. Clin Infect Dis. 1994;18(suppl 1):S79-S83.
43. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186-1196.
44. Carskadon MA, Dement WC, Mitler MM, et al. Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness. Sleep. 1986;9(4):519-524.
45. Mitler MM, Gujavarty KS, Browman CP. Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol. 1982;53(6):658-661.
46. American Academy of Sleep Medicine. Practice parameters for clinical use of the Multiple Sleep Latency Test and the Maintenance of Wakeful-ness Test. Sleep. 2005;28(1):113-121.
47. Wise MS. Objective measures of sleepiness and wakefulness: application to the real world? J Clin Neurophysiol. 2006;23(1):39-49.
48. Loube DI, Gay PC, Strohl KP, et al. Indications for positive airway pressure treatment of adult obstructive sleep apnea patients: a consensus statement. Chest. 1999;115(3):863-866.
49. Faccenda JF, Mackay TW, Boon NA, et al. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med. 2001;163(2):344-348.
50. Engleman HM, Martin SE, Deary IJ, et al. Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/ hypopnoea syndrome. Lancet. 1994;343(8897):572-575.
51. Jenkinson C, Davies RJ, Mullins R, et al. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet. 1999; 353(9170):2100-2105.
52. Patel SR, White DP, Malhotra A, et al. Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea. Arch Intern Med. 2003;163(5):565-571.
53. Sforza E, Krieger J. Daytime sleepiness after long-term continuous positive airway pressure (CPAP) treatment in obstructive sleep apnea syndrome. J Neurol Sci. 1992;110(1-2):21-26.
54. Bedard M-A, Montplaisir J, Malo J, et al. Persistent neuropsychological deficits and vigilance impairment in sleep apnea syndrome after treatment with continuous positive airways pressure (CPAP). J Clin Exp Neuropsychol. 1993;15(2):330-341.
55. Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep. 2007;30(6):711-719.
56. Schwartz JR, Roth T. Shift work sleep disorder: burden of illness and approaches to management. Drugs. 2006;66(18):2357-2370.
57. Lu BS, Zee PC. Circadian rhythm sleep disorders. Chest. 2006;130(6): 1915-1923.
58. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93(24):14128-14133.
59. Saper CB, Scammell TE. Modafinil: a drug in search of a mechanism. Sleep. 2004;27(1):11-12.
60. Myrick H, Malcolm R, Taylor B, et al. Modafinil: preclinical, clinical, and post-marketing surveillance: a review of abuse liability issues. Ann Clin Psychiatry. 2004;16(2):101-109.
61. Sackner-Bernstein J, Niebler G, Earl CQ. Cardiovascular profile of modafinil: effects on blood pressure and heart rate. Chest. 2004; 126:729S.
62. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761-774.
63. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006;28(5):689-706.
64. Drake C, Walsh J, Roth T. Armodafinil improves sleep latency in patients with shift work sleep disorder. Sleep. 2006;29(suppl):A64.
65. Rosenberg R, Walsleben J. Armodafinil reduces daytime fatigue associated with excessive sleepiness in patients with obstructive sleep apnea or narcolepsy. Sleep. 2006;29(suppl):A228.
66. Littner M, Johnson SF, McCall W V, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep. 2001;24(4): 451-466.
67. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005;28(4):464-471.
68. Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med. 2001;164(9):1675-1681.
69. Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift work sleep disorder. N Engl J Med. 2005;353(5):476-486.
70. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 1998;43(1):88-97.
71. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54(5):1166-1175.
72. Beusterien KM, Rogers AE, Walsleben JA. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999;22(6): 757-765.
73. Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med. 2003;4(5):393-402.
74. Erman MK, Rosenberg R, For the US Modafinil Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life. Prim Care Companion J Clin Psychiatry. 2007;9(3):188-194.
75. Roth T, Czeisler CA, Walsh JK, et al. Randomized, double-blind, placebo-controlled study of armodafinil for the treatment of excessive sleepiness associated with chronic shift work sleep disorder. Neuropsychopharmacol. 2005;30(suppl 1s):S140.
76. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med. 2007;101(3):616-627.
77. Provigil [package insert]. Frazer, PA: Cephalon, Inc; 2007.
78. Nuvigil, Frazer, PA: Cephalon, Inc; 2007. [FDA-approved label].
79. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4): 391-397.
80. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939-946.
81. Xyrem [package insert]. Palo Alto, CA: Jazz Pharmaceuticals.